In the BioHarmony Drug Report Database

"Preview" Icon

Obiltoxaximab

Anthim, Obiltoxaximab SFL (obiltoxaximab) is an antibody pharmaceutical. Obiltoxaximab was first approved as Anthim on 2016-03-18. It is used to treat anthrax, crohn disease, and graft vs host disease in the USA. It has been approved in Europe to treat anthrax.

 

Trade Name

 

Obiltoxaximab SFL
 

Common Name

 

obiltoxaximab
 

ChEMBL ID

 

CHEMBL3544926
 

Indication

 

anthrax, crohn disease, graft vs host disease
 

Drug Class

 

Monoclonal antibodies: toxin as a target

Image (chem structure or protein)

Obiltoxaximab structure rendering